| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
James J /ky Obrien is Director at EMN and has filed Form 4s across 3 companies. James J /ky Obrien's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.1M at current prices.
The biggest single holding is HUM (~$750K) as Director. The HUM filings lean toward selling, a net 2,500 shares.
James J /ky Obrien has 56 Form 4 filings on record from February 2015 to October 2026, across 4 companies: Director at Eastman Chemical (EMN), 2016–2026; Director at Albemarle (ALB), 2015–2025; Director at Humana (HUM), 2018–2023, and 1 more.
The 65 reported transactions were 40 option or other derivative awards, 15 stock awards, 6 open-market purchases and 3 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $152K and 1 sale worth about $855K.
The largest open-market purchase was 1,450 shares of EMN at an average $68.81 on August 27, 2025, about $100K. Twelve months later EMN was up 6%.
The only open-market sale was 2,500 shares of HUM at an average $341.95 on December 3, 2019, about $855K.